133627-47-1

Basic information

• Product Name: 3-PyridineCarboxamide,Nevirapine
• Synonyms: 3-PyridineCarboxamide,Nevirapine;N-(2-Lhioro-4-Methyi-J-Pyndinyl)-2-(Cyclopropyi Amino)-3-Pyridine Carboxamide;N-(2-Chioro-4-Methyi-3-Pyndinyl)-2-(Cyclopropyi AMino)-3-Pyridine CarboxaMide;N-(2-chloro-4-methylpyridin-3-yl)-2-(cyclopropylamino)pyridine-3-carboxamide
• CAS NO: 133627-47-1
• Molecular Formula: C₁₅H₁₅ClN₄O
• Molecular Weight: 302.7588
• Mol File: 133627-47-1.mol
• Article Data: 9

Chemical Properties

• Melting Point: 127-129 °C
• Boiling Point: 428.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.429±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 11.17±0.70(Predicted)
• CAS DataBase Reference: 3-PyridineCarboxamide,Nevirapine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PyridineCarboxamide,Nevirapine(133627-47-1)
• EPA Substance Registry System: 3-PyridineCarboxamide,Nevirapine(133627-47-1)

Safety Data

• Hazardous Substances Data: 133627-47-1(Hazardous Substances Data)

Usage

Description

3-PyridineCarboxamide,Nevirapine, also known as N-(2-Chloro-4-methylpyridin-3-yl)-2-(cyclopropylamino)nicotinamide, is a synthetic intermediate and an impurity of Nevirapine (CAS# 133627-47-1). It is a chemical compound derived from the pyridine carboxamide class and is used in the pharmaceutical industry for the development of antiviral and antiretroviral drugs.

Uses

Used in Pharmaceutical Industry:
3-PyridineCarboxamide,Nevirapine is used as a synthetic intermediate for the development of antiviral and antiretroviral drugs, specifically for the production of Nevirapine. It plays a crucial role in the synthesis process, contributing to the overall effectiveness of the final drug product.
As an impurity in Nevirapine:
3-PyridineCarboxamide,Nevirapine is also recognized as an impurity in Nevirapine (N391275). It is essential to monitor and control the levels of this impurity during the manufacturing process to ensure the safety, efficacy, and quality of the final drug product. The presence of impurities can affect the drug's performance and may lead to potential side effects or reduced therapeutic outcomes.

Upstream product

• 133627-46-0 2-chloro-N-(2-chloro-4-methyl-3-pyridinyl)-3-pyridinecarboxamide 
• 765-30-0 Cyclopropylamine 
• 49609-84-9 2-Chloronicotinoyl chloride 
• 2942-59-8 2-chloronicotinic acid 
• 23056-39-5 2-chloro-3-nitro-4-methylpyridine 
• 133627-45-9 3-Amino-2-chloro-4-methylpyridine 
• 639807-18-4 2-(cyclopropylamino)pyridine-3-carboxylic acid 
• 65169-38-2 2-chloro-4-methyl-3-pyridinecarbonitrile 
• 152362-01-1 2-chloro-4-methyl-3-pyridinecarboxamide 
• 6602-54-6 2-chloro-3-pyridinecarbonitrile 
• 52583-90-1 2-cyclopropylaminonicotinonitrile 
• 71493-72-6 2-(4-(dimethylamino)but-3-en-2-ylidene)malononitrile 
• 111-96-6 diethylene glycol dimethyl ether 
• 13166-10-4 isopropylidenemalonodinitrile 

Downstream Products

• 129618-40-2 Nevirapine 

Relevant articles and documents

Increasing global access to the high-volume HIV drug nevirapine through process intensification

Access to affordable medications continues to be one of the most pressing issues for the treatment of disease in developing countries. For many drugs, synthesis of the active pharmaceutical ingredient (API) represents the most financially important and technically demanding element of pharmaceutical operations. Furthermore, the environmental impact of API processing has been well documented and is an area of continuing interest in green chemical operations. To improve drug access and affordability, we have developed a series of core principles that can be applied to a specific API, yielding dramatic improvements in chemical efficiency. We applied these principles to nevirapine, the first non-nucleoside reverse transcriptase inhibitor used in the treatment of HIV. The resulting ultra-efficient (91% isolated yield) and highly-consolidated (4 unit operations) route has been successfully developed and implemented through partnerships with philanthropic entities, increasing access to this essential medication. We anticipate an even broader global health impact when applying this model to other active ingredients.

Process for preparing Nevirapine

An improved process for preparing 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one of Formula (I).

AN IMPROVED PROCESS FOR PREPARING NEVIRAPINE

An improved process for preparing 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido [3,2-b:2',3'-e][1,4] diazepin-6-one of Formula (I).